RxDoctor Payments Data

Jayadeuan Kundumadathil, MD

Internal Medicine · Indialantic, FLNPI 1912968918

Payments from drug & device makers

$2,347in general payments, 2019–2025

Across 128 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$982
  • AstraZeneca$476
  • Lilly USA, LLC$259
  • Boehringer Ingelheim$162
  • Novocure Inc.$85
  • Bayer$61
  • plus $323 from 13 others

What the payments were for

  • Food & beverage$2,32799%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,347 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$159,961
Medicare patients
301
Services billed
1,330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$121,768
FarxigaDapagliflozin Propanediol75$75,946
JardianceEmpagliflozin66$61,700
OzempicSemaglutide43$56,544
BiktarvyBictegrav/Emtricit/Tenofov Ala12$46,819
MounjaroTirzepatide37$44,498
XareltoRivaroxaban25$32,034
LinzessLinaclotide19$10,729
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$7,632
Rosuvastatin Calcium455$6,870
Valsartan134$5,218
Atorvastatin Calcium411$4,330
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,863
Levothyroxine Sodium311$3,668
Lisinopril358$2,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$121,768108 claims
AstraZenecaFarxiga$476$75,94675 claims
Boehringer IngelheimJardiance$162$61,70066 claims
Novo NordiskOzempic$982$56,54443 claims
Lilly USA, LLCMounjaro$259$44,49837 claims
AbbVieLinzess, Synthroid$14$11,91541 claims
GSKAnoro Ellipta$13$7,63218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Indialantic

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →